Gui-qi F. Zhu

Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Targeting HMGB2 acts as dual immunomodulator by bolstering CD8+ T cell function and inhibiting tumor growth in hepatocellular carcinoma.

Targeting HMGB2 acts as dual immunomodulator by bolstering CD8+ T cell function and inhibiting tumor growth in hepatocellular carcinoma.

Journal: Science advances

Published: May 02, 2025

Downregulation of GPX8 in hepatocellular carcinoma: impact on tumor stemness and migration.

Downregulation of GPX8 in hepatocellular carcinoma: impact on tumor stemness and migration.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: March 05, 2024

Targeting SRSF1 improves cancer immunotherapy by dually acting on CD8+T and tumor cells.

Targeting SRSF1 improves cancer immunotherapy by dually acting on CD8+T and tumor cells.

Journal: Signal transduction and targeted therapy

Published: February 07, 2024

Deciphering intratumoral heterogeneity of hepatocellular carcinoma with microvascular invasion with radiogenomic analysis.

Deciphering intratumoral heterogeneity of hepatocellular carcinoma with microvascular invasion with radiogenomic analysis.

Journal: Journal of translational medicine

Published: June 14, 2023

Targeting IRG1 reverses the immunosuppressive function of tumor-associated macrophages and enhances cancer immunotherapy.

Targeting IRG1 reverses the immunosuppressive function of tumor-associated macrophages and enhances cancer immunotherapy.

Journal: Science advances

Published: April 28, 2023

Development of a deep pathomics score for predicting hepatocellular carcinoma recurrence after liver transplantation.

Development of a deep pathomics score for predicting hepatocellular carcinoma recurrence after liver transplantation.

Journal: Hepatology international

Published: December 02, 2022

CD36+ cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor.

CD36+ cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor.

Journal: Cell discovery

Published: November 17, 2022

Single-cell and spatial architecture of primary liver cancer.

Single-cell and spatial architecture of primary liver cancer.

Journal: Communications biology

Published: September 25, 2022

Prognostic value of combined pre- and postoperative albumin-to-alkaline phosphatase ratio for patients with hepatocellular carcinoma undergoing trans-catheter chemoembolisation.

Prognostic value of combined pre- and postoperative albumin-to-alkaline phosphatase ratio for patients with hepatocellular carcinoma undergoing trans-catheter chemoembolisation.

Journal: Clinical radiology

Published: July 27, 2022

Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study.

Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study.

Journal: BJS open

Published: May 19, 2022

LncRNA USP2-AS1 Promotes Hepatocellular Carcinoma Growth by Enhancing YBX1-Mediated HIF1α Protein Translation Under Hypoxia.

LncRNA USP2-AS1 Promotes Hepatocellular Carcinoma Growth by Enhancing YBX1-Mediated HIF1α Protein Translation Under Hypoxia.

Journal: Frontiers in oncology

Published: February 23, 2022

Crosstalk Between Metabolism and Immune Activity Reveals Four Subtypes With Therapeutic Implications in Clear Cell Renal Cell Carcinoma.

Crosstalk Between Metabolism and Immune Activity Reveals Four Subtypes With Therapeutic Implications in Clear Cell Renal Cell Carcinoma.

Journal: Frontiers in immunology

Published: January 24, 2022

Showing 1-12 of 37

Last Updated: 09/26/2026